Abstract
The approved biologics targeting interleukin (IL)-23 p19 for the treatment of moderate-to-severe plaque psoriasis, including guselkumab, tildrakizumab, and risankizumab, have generally favorable safety profiles. The aim of the current review is to describe in detail the safety of these selective inhibitors. A literature search was performed using PubMed from inception to 1 November 2022, to identify clinical trials and real-world evidence publications using the keywords “guselkumab,” “tildrakizumab,” and “risankizumab.” Overall, the most common adverse events (AEs) associated with IL-23 p19 inhibitors in clinical trials were nasopharyngitis, headache, and upper respiratory tract infections. Rates of serious AEs and AEs of interest, including serious infections, nonmelanoma skin cancer (NMSC), malignancies excluding NMSC, major adverse cardiovascular events, and serious hypersensitivity reactions, were not increased with long-term use in clinical trials. Selectively targeting IL-23 p19 was also not associated with elevated risk of opportunistic infections, tuberculosis reactivation, oral candidiasis, or inflammatory bowel disease. Results from real-world studies were similar, supporting the safe long-term use of these biologics in a wider population of patients with psoriasis, including older patients, patients for whom multiple biologics failed, and those with comorbidities such as obesity, metabolic syndrome, cardiovascular disease, dyslipidemia, diabetes, hypertension, and psoriatic arthritis. This review is limited by the lack of direct comparisons among therapeutic agents due to differences among study designs and safety data reporting methods. In conclusion, the favorable safety profiles of IL-23 p19 inhibitors support their long-term use in the management of patients with moderate-to-severe psoriasis.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Novel biologic therapies have quickly emerged as an effective psoriasis treatment; however, psoriasis is a life-long disease, and long-term inhibition of the immune system comes with a few safety concerns, including increased risk of infections and malignancies. |
Cumulative evidence from clinical trials demonstrates the favorable safety profile of interleukin (IL)-23 p19 inhibitors. |
Safety concerns associated with other biologics occurred infrequently, and the most common adverse events were nasopharyngitis, upper respiratory tract infection, and headache. |
Real-world studies support the safety of long-term use of IL-23 p19 inhibitors in a wider population of patients with psoriasis, including older patients, patients for whom multiple biologics have failed, and patients with comorbidities. |
Introduction
Psoriasis is an immune-mediated disease characterized by chronic inflammation in skin, joints, and other tissues, with an estimated prevalence of 3% in US adults [1]. It is associated with a number of comorbid conditions, including psoriatic arthritis (PsA), cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, and mood disorders [2,3,4]. Topical therapy is the mainstay of psoriasis treatment in patients with limited disease (about 70–80% of patients), while systemic therapies, including biologics, are used in patients with more widespread disease, disease resistant to topical therapy, and/or involvement of special skin areas [5,6,7].
Biologics target cytokines involved in psoriasis physiopathology (e.g., tumor necrosis factor-alpha [TNF-α] and the interleukins [IL] IL-23 and IL-17). Of these cytokines, IL-23 is considered the major regulatory cytokine in psoriasis pathogenesis, whereas IL-17 is considered the main effector cytokine [8]. IL-23 acts “upstream” of T-helper 17 cells, which are dependent on IL-23 for survival, proliferation, and IL-17A/F production [3, 9]. Currently approved drugs that selectively target IL-23 via its unique p19 domain include guselkumab, tildrakizumab, and risankizumab [3]. These agents offer robust efficacy, favorable safety profiles, and convenient dosing (every 2–3 months) for patients with psoriasis. The p40 subunit of IL-23, which is shared with IL-12, was also identified as a therapeutic target for psoriasis [9]. Currently, ustekinumab is the only human monoclonal antibody targeting the p40 subunit of IL-12 and IL-23 indicated for the treatment of moderate-to-severe psoriasis [10]. Overall, the effectiveness and safety of ustekinumab were demonstrated in patients with psoriasis regardless of age and sex [10, 11].
The aim of the current review is to describe in detail the safety of selective IL-23 p19 inhibitors. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Methods
A literature search was performed using PubMed from inception to 1 November, 2022, to identify clinical trials and real-world evidence publications using the keywords “guselkumab,” “tildrakizumab,” and “risankizumab.” Only studies published in English were considered.
Overview of General Safety Concerns of Biologics
Table 1 lists biologics approved by the US Food and Drug Administration (FDA) for the treatment of patients with moderate-to-severe plaque psoriasis, with an overview of safety concerns for each agent/class [3, 4]. TNF inhibitors are associated with increased risk of serious infections, including opportunistic infections, tuberculosis (TB), and hepatitis B reactivation. Although reactivation of latent TB is listed as a safety consideration for all biologics used for psoriasis, this problem is most commonly reported with TNF inhibitors [4]. TNF inhibitors also have labeled warnings for lymphoma, nonmelanoma skin cancer (NMSC), congestive heart failure, demyelinating disease, lupus, infusion reactions (with infliximab), and transaminitis [12,13,14,15]. Concerns with the use of IL-17 and IL-17 receptor inhibitors include infections (notably candidiasis), neutropenia, inflammatory bowel disease (IBD), and suicidal ideation and behavior [16,17,18]. Regarding immunogenicity, adalimumab and infliximab are associated with higher rates of antidrug antibody development versus other biologics used for psoriasis [19]. The effect of immunogenicity on efficacy and safety of newer biologic agents does not seem to be clinically relevant [20]. For the IL-12/23 inhibitor ustekinumab, safety considerations include infections, TB, malignancies, hypersensitivity reactions, posterior reversible encephalopathy syndrome, and noninfectious pneumonia [10]. For the IL-23 p19 inhibitors guselkumab, tildrakizumab, and risankizumab, listed safety precautions are limited to infections, hypersensitivity reactions, and TB [21,22,23].
Safety of IL-23 p19 Inhibitors
Guselkumab
The safety profile of guselkumab 100 mg in the Phase 3, double-blinded, active comparator-controlled studies (VOYAGE 1, VOYAGE 2, NAVIGATE, and ECLIPSE) was favorable for up to 60 weeks in adult patients with moderate-to-severe plaque psoriasis (Table 2). Nasopharyngitis (7–25%) and upper respiratory tract infection (URTI; 3–16%) were the most commonly reported adverse events (AEs); 1–7% of patients experienced a serious AE (SAE), and 1–3% of patients discontinued the study because of an AE. For AEs of interest, infection was commonly reported (22–59%), although few patients had serious infections (0–1%).
In VOYAGE 1 and VOYAGE 2, the SAEs reported for guselkumab and adalimumab during the active comparator-controlled period (5% in both groups for weeks 0–48 and 4% in both groups for weeks 0–28, respectively) were similar to those reported during the placebo-controlled period [24, 25]. In NAVIGATE, 7% of patients receiving guselkumab and 5% of those receiving ustekinumab had at least one serious AE between weeks 16 and 60; the rate of infections requiring antibiotic treatment was slightly higher in guselkumab-treated patients (16% vs. 10%) [26]. The AEs observed in the ECLIPSE trial were generally similar between guselkumab-treated and secukinumab-treated patients, with the exception of slightly higher rates of Candida (6% vs. 2%) and Tinea (5% vs. 2%) infections during secukinumab versus guselkumab treatment [27]. Rates of serious infections, malignancies, and major adverse cardiovascular events (MACE) were comparable across treatment arms [24,25,26,27].
Periodic assessment of long-term guselkumab treatment has shown a consistent safety profile after 2 years [28], 3 years [29], and 5 years of treatment [30]. Overall, 78% (1349/1721) of guselkumab-treated patients continued treatment through 5 years [30]. There were no safety signals of concern for serious infection, malignancy (including NMSC), or MACE among guselkumab-treated patients, and the rates of these AEs of interest were either stable or decreased over time [29]. Over 7166 patient-years (PYs), the rates of overall AEs and SAEs were 149.0 and 5.0 events per 100 PYs, respectively. Individual AEs of interest occurred at event rates of < 1 per 100 PYs; these included serious infections (0.9 per 100 PYs), NMSC (0.3), malignancies other than NMSC (0.5), and MACE (0.3) [30]. Over the entire study period, 32 guselkumab-treated patients were diagnosed with malignancies, most commonly breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and lymphoma. Rates of malignancy (excluding NMSC) were generally consistent with estimates in the general US population and observations in patients with psoriasis (PSOLAR population), suggesting no association between guselkumab and increased risk of cancer in patients with psoriasis [31]. During the 5-year study period, five deaths occurred in VOYAGE 1 and four deaths in VOYAGE 2 among guselkumab-treated patients [30].
Long-term treatment with guselkumab was well tolerated in patients receiving treatment for latent TB. In the VOYAGE 1 and VOYAGE 2 studies, 69 (8%) patients in the guselkumab group and 36 (6%) patients in the adalimumab group had latent TB at baseline and received treatment for TB through week 100; no new cases of active TB, including no reactivation of latent TB, were reported in either group [32]. No cases of inflammatory bowel disease (IBD) were observed in pooled data from VOYAGE 1 and VOYAGE 2, and the rate of gastrointestinal SAEs was 0.5 events per 100 PYs through 4 years [33].
A post hoc analysis of VOYAGE 1 and VOYAGE 2 results reported generally similar tolerability at weeks 16 and 28 for Asian (n = 94) and non-Asian patients (n = 729) treated with guselkumab [34]. Compared with non-Asian patients, a higher frequency of Asian patients had ≥ 1 AE at week 16 (Asian versus. non-Asian patients, 61% vs. 48%) and week 28 (72% vs. 59%); the frequency of SAEs was 1% versus. 4%, and the frequency of discontinuation due to AEs was 2% in both groups, at week 28 [34]. A subgroup analysis of Korean patients from VOYAGE 1 and VOYAGE 2 (n = 126) reported similar frequencies of AEs in all treatment arms at weeks 16 and 28, with the exception of a much higher frequency of injection site reactions in adalimumab-treated patients (24% vs. 3–7%) [35]. A placebo-controlled Phase 3 trial conducted in 159 Japanese patients with palmoplantar pustulosis also reported good tolerability for guselkumab 100 and 200 mg, with similar or lower rates of AEs, SAEs, treatment-related AEs, and AEs leading to discontinuation in patients treated with guselkumab versus placebo [36]. In another post hoc analysis of 18 patients in VOYAGE 1 and VOYAGE 2 with a history of malignancy with no recurrence for ≥ 5 years at baseline, three patients had SAEs of malignancy (excluding NMSC) during guselkumab treatment [37]. There were also two diagnoses of NMSC among the 18 patients [37].
Guselkumab remained well tolerated in real-world studies, most of which were small, retrospective, and/or in special populations, with similar types (nasopharyngitis, URTI, flu-like illness) and overall lower frequencies of AEs compared with clinical trial results (Table 3). Guselkumab was well tolerated in patients with a previous failure of ustekinumab and/or IL-17 inhibitor therapy [38, 39], in overweight/obese patients [40, 41], in heavily pretreated patients (mean of 4 prior biologics) [42], and in older patients (mean age 71 years) with multiple comorbidities [43]. Data from one of the larger (N = 307) real-world studies conducted in Italy reported AEs in only ten patients (3%); all AEs were mild in severity with the exception of one transient ischemic attack, and two patients (1%) discontinued guselkumab due to an AE (erythroderma and general malaise, n = 1 each) [44].
In a larger (N = 303) prospective 52-week real-world study conducted in Germany, 15% of guselkumab-treated patients experienced at least one treatment-related AE; the majority of AEs were mild/moderate in severity, and 3% of patients discontinued due to an AE [45]. Four (1%) treatment-related SAEs were reported, including bronchitis, Epstein-Barr virus infection, malignant neoplasm, and pemphigoid (n = 1 each) [45]. A small Italian study in 31 patients with follow-up for 3 years reported common AEs of pharyngitis (23%), headache (16%), and flu-like illness (16%), with no SAEs, Candida infection, malignancy, or cardiovascular events [51].
Tildrakizumab
Tildrakizumab has a favorable safety profile for up to 5 years in patients with moderate-to-severe plaque psoriasis and is considered safe for use in patients with IBD, cardiovascular disease, and metabolic syndrome, as well as in older patients [56]. Tildrakizumab was well tolerated through week 28 in two Phase 3 pivotal trials in patients with moderate-to-severe plaque psoriasis: reSURFACE 1 and reSURFACE 2 (Table 4) [57]. In reSURFACE 1, patients received tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo; in reSURFACE 2, patients received tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg [57]. In reSURFACE 1, nasopharyngitis (4–8%) and URTI (3–7%) were the most commonly reported AEs among patients treated with tildrakizumab and placebo at weeks 12 and 28 [57]. In reSURFACE 2, nasopharyngitis (4–14%) and injection site erythema (0–9%, more frequently reported in etanercept-treated patients) were the most commonly reported AEs across all treatment arms [57]. SAEs during tildrakizumab treatment were reported in approximately 2% of patients in both trials, and approximately 1% of patients discontinued because of an AE. Frequencies of AEs of interest, including severe infections, malignancies, NMSC, MACE, and drug-related hypersensitivities, were similar across treatment arms [57]. Across both trials, seven patients had history of IBD (3 patients in tildrakizumab 200 mg arm, 3 in tildrakizumab 100 mg arm, and 1 in placebo treatment group) [58]; no new cases or exacerbations of IBD were reported [57]. Pooled data from the reSURFACE 1 and reSURFACE 2 trials as well from a Phase 2b study (N = 2081) up to 64 weeks showed reassuring event rates (calculated as patients with events) for any AEs and AEs of interest per 100 PYs of exposure to tildrakizumab 100 and 200 mg, including treatment-related AEs (23.3 and 25.2 for any AEs and AEs of interest per 100 PYs of exposure, respectively), treatment-related SAEs (0.3 and 1.0), MACE (0.4 and 0.3), severe infections (1.1 and 1.6), Candida skin infections (0.2 and 0.7), malignancies (1.7 and 1.2), NMSC (1.1 and 0.9), melanoma (0.2 and 0), injection site reactions (3.5 and 4.6), and drug-related hypersensitivity (0.5 and 0.2) [59].
Long-term pooled safety data after up to 3 and 5 years of treatment are reported for reSURFACE 1 and reSURFACE 2. At 3 years, event rates (patients with events) per 100 PYs for the most commonly reported AEs during treatment with tildrakizumab 100 mg (2014 PYs of follow-up) and 200 mg (2047 PYs) were nasopharyngitis (10.2 and 9.8, respectively), viral URTI (6.9 and 6.7), URTI (3.8 and 5.6), arthralgia (3.4 and 2.8), headache (2.7 and 3.1), and influenza (2.4 and 3.2) [60]. For overall safety outcomes, the corresponding event rates were as follows: AEs (35.2 and 37.2), SAEs (5.9 and 5.5), deaths (0.3 and 0.2), drug-related AEs (11.4 and 12.9), drug-related SAEs (0.8 and 0.5), discontinuations due to AEs (1.7 and 1.2), discontinuations due to SAEs (0.9 and 0.8), discontinuations due to drug-related AEs (0.7 and 0.3), and discontinuations due to drug-related SAEs (0.4 and 0.2) [60]. Exposure-adjusted rates of AEs were generally similar between patients treated with tildrakizumab 100 versus 200 mg and among patients treated with tildrakizumab versus placebo (205 PYs) or etanercept (153 PYs) [60]. Event rates of AEs of special interest were < 2.5 per 100 PYs in patients treated with tildrakizumab 100 mg and 200 mg, including for severe infection (1.1 and 1.1), malignancy excluding NMSC (0.6 and 0.4), NMSC (0.5 and 0.5), melanoma (0.1 and 0.0), MACE (0.4 and 0.5), injection site reactions (1.9 and 2.3), and drug-related hypersensitivity reactions (0.3 and 0.2) [60].
Five-year pooled safety data are available for reSURFACE 1 (256 weeks) and reSURFACE 2 (244 weeks) and are presented for patients who received tildrakizumab 100 mg (n = 872; 2688 PYs of follow-up) or 200 mg (n = 928; 2754 PYs of follow-up) [61]. Rates of AEs and AEs of interest did not increase over time. The types and rates (of patients with AEs) per 100 PYs for the tildrakizumab 100 mg and 200 mg groups after 5 years were similar to those reported at 3 years, including nasopharyngitis (10.5 and 10.7, respectively), URTI (3.8 and 4.6), hypertension (3.0 and 3.3), influenza (2.4 and 3.1), arthralgia (3.0 and 3.0), back pain (2.4 and 2.7), and headache (2.3 and 2.6) [61]. Over 5 years of treatment, only one suspected case of new-onset Crohn’s disease was reported; the event was mild and did not lead to discontinuation [61]. Event rates per 100 PYs for tildrakizumab 100 mg and 200 mg, respectively, for drug-related AEs (9.3 and 9.8), drug-related SAEs (0.8 and 0.5), deaths (0.3 and 0.2), drug-related AEs leading to discontinuation (0.7 and 0.3), and drug-related SAEs leading to discontinuation (0.3 and 0.2) were similar to those reported at 3 years, as were the rates of AEs of interest [61].
In post hoc analyses of reSURFACE 1 and reSURFACE 2 data, the long-term (5 years) safety profile of tildrakizumab was similar regardless of body weight [62] or presence of metabolic syndrome (Table 5) [63]. Five-year rates of AEs and AEs of interest during treatment with tildrakizumab 100 mg and 200 mg were similar between patients with psoriasis weighing < 120 kg and those weighing ≥ 120 kg [62]. The combined rates (patients with events) of AEs of special interest (drug hypersensitivity, serious infections, malignancies, melanoma, NMSC, MACE, and injection site reactions) for patients without and with metabolic syndrome, respectively, were 2.1 and 2.0 for tildrakizumab 100 mg and 2.6 and 5.2 for tildrakizumab 200 mg [63]. For SAEs, the corresponding event rates per 100 PYs were 4.6 and 7.2 for tildrakizumab 100 mg in patients without and with metabolic syndrome, respectively, and 4.9 and 8.4 for tildrakizumab 200 mg in patients without and with metabolic syndrome; gastrointestinal disorders, neoplasm, infections and infestations, and cardiac disorders were the most common SAEs [63]. Rates of respiratory or viral infections did not appear to increase over 5 years of tildrakizumab treatment [64]. Treatment with tildrakizumab for up to 3 years did not increase the risk for cardiovascular events, including MACE, in patients with already high rates of cardiovascular- and/or metabolic-related conditions at baseline (87–88%) [65]. Measures of cardiometabolic disease risk factors (fasting serum glucose, low/high-density lipoprotein cholesterol, total cholesterol, triglyceride levels, body weight, and blood pressure) at 1 year were not significantly different between reSURFACE 1 and reSURFACE 2 patients with versus those without metabolic syndrome [66].
Tildrakizumab treatment for up to 5 years was well tolerated in patients aged > 65 years, and the rates of AEs and AEs of interest in this population were in line with those in the overall trial population; no dose-related increase in AE rates was observed (Table 5) [67]. Long-term treatment with tildrakizumab was also well tolerated in the small subgroup (n = 129) of Japanese patients in reSURFACE 1; event rates (patients with events) per 100 PYs for AEs of special interest for tildrakizumab 100 and 200 mg, respectively, were 1.0 and 1.4 for severe infection, 0.7 and 0.6 for malignancies, 0 for any skin cancer, and 1.4 and 0.3 for MACE [68].
Tildrakizumab was well tolerated in real-world studies, most of which were small and retrospective, with lower frequencies of AEs relative to those reported in clinical trials; most studies reported generally mild AEs, no safety issues, and no discontinuations due to AEs (Table 5). In one of the larger real-world studies (N = 412) of tildrakizumab, conducted in Germany, 68 (15%) patients experienced an AE (16.5 patients with events per 100 PYs) and 14 (3%) experienced a SAE (3.4 patients with events per 100 PYs) at 52 weeks of follow-up [69]. Similarly, AEs were reported in 5% of 237 Italian patients treated with tildrakizumab for 52 weeks, and no patients discontinued treatment due to an AE [70], consistent with the results from other real-world studies conducted in Germany (3/150 [2%] patients switched to another treatment due to an AE [71]) and in the UK (AEs reported in 6/113 [5%] patients; 1 patient [0.9%] discontinued due to an AE [72]).
Risankizumab
Risankizumab was well tolerated in clinical trials and in a long-term extension study for up to 4 years. The safety of risankizumab 150 mg has been assessed in five Phase 3 trials: UltIMMa 1 and 2, risankizumab versus placebo and ustekinumab; IMMvent, risankizumab versus adalimumab; IMMhance, risankizumab versus placebo; and IMMerge, risankizumab versus secukinumab (Table 6). Risankizumab was well tolerated during weeks 0–16 (part A) and weeks 16–52 (part B) in UltIMMa 1 and 2, with similar percentages of risankizumab-treated patients in both trials experiencing ≥ 1 AE (risankizumab-treated patients in UltIMMa 1 and 2: part A, 49.7% and 45.6%, respectively; part B, 61.3% and 55.7%, respectively) and ≥ 1 SAE (risankizumab-treated patients in UltIMMa 1 and 2: part A, 2.3% and 2.0%, respectively; part B, 5.4% and 4.5%, respectively); AE frequencies were similar or higher in patients treated with placebo and ustekinumab [75]. The proportion of patients with AEs leading to drug discontinuation was < 5% across all groups [75]. The most frequently reported AEs in part A in both trials were viral URTI, URTI, psoriasis, and diarrhea, while the most frequently reported AEs in part B in both trials were viral URTI, URTI, urinary tract infection, influenza, and headache (Table 6) [75]. The rates of AEs of interest were similar across treatment arms; through week 52, MACE was reported in two patients with preexisting cardiovascular risk factors, and neither event was considered related to risankizumab [75].
In the IMMvent trial, the frequencies of AEs, SAEs, and AEs leading to study drug discontinuation were unremarkable in patients treated with either risankizumab or adalimumab during weeks 0–16 (part A) and among those patients rerandomized to risankizumab during weeks 16–44 (part B) [76]. The most frequently reported AEs were viral URTI and URTI (Table 6). Through week 48, individual AEs of interest occurred in ≤ 3.5% of risankizumab-treated patients; during parts A and B, respectively, serious infection occurred in < 1% and 1%, opportunistic infection in 0% and 1%, latent TB in 0% and < 1%, MACE in < 1% and 0%, hepatic events in 2% and 3%, and malignancy in < 1% and 1% of risankizumab-treated patients [76]. There were no reported cases of ulcerative colitis or Crohn’s disease [76].
In the IMMhance trial, patients received risankizumab at weeks 0 and 4 (weeks 0–16; part A1) and at week 16 (part A2); at week 28, patients with response (static Physician’s Global Assessment 0/1) [77] received risankizumab every 12 weeks thereafter (weeks 28–88; part B) [77]. The types and rates of AEs in IMMhance parts A1 and B were consistent with those observed in other Phase 3 trials of risankizumab (Table 6). Overall, AEs were reported in 426 patients (85%; 259.7 events per 100 PYs) and SAEs in 55 patients (11%; 13.5 events per 100 PYs) receiving risankizumab at any point during the trial [77]. The most frequently reported AEs were nasopharyngitis (23%), URTI (15%), headache (7%), and back pain (6%) [77]. There were no reports of active or latent TB or serious hypersensitivity among patients receiving risankizumab, and event rates per 100 PYs were 1.4 for serious infections and 2.2 for cancers [77]. Hepatic events were reported in 23 patients (4.6%), one (0.2%) of which was a serious event (hepatic cirrhosis) [77]. Six cases of MACE were reported in four patients (0.8%; 0.9 events per 100 PYs), including three strokes, two myocardial infarctions, and one cardiovascular death (unknown cause); none were considered to be related to risankizumab [77]. Death occurred in four patients (0.8%; 1 each for epileptic seizure and metastatic hepatic cancer, and 2 of unknown cause), none of which were considered related to risankizumab [77].
In the IMMerge trial, the rates of AEs, SAEs, drug-related AEs, and drug-related SAEs were similar between patients treated with risankizumab and secukinumab [78]. Eight (5%) patients in the secukinumab arm discontinued study treatment because of AEs, compared with two (1%) patients in the risankizumab arm [78]. The most commonly reported AEs were nasopharyngitis, URTI, headache, arthralgia, and diarrhea (Table 6) [78]. Among AEs of interest, MACE (nonfatal myocardial infarction) was reported in two risankizumab-treated patients versus no secukinumab-treated patients; both risankizumab-treated patients with MACE had multiple cardiovascular risk factors, and neither event was considered related to the study drug [78]. Three risankizumab-treated patients experienced serious infections (urinary tract infections, n = 2; histiocytic necrotizing lymphadenitis, n = 1) [78]. One case of new-onset ulcerative colitis occurred in a patient treated with secukinumab (considered to be serious and related to treatment, and led to treatment discontinuation) [78]. Candida infections (including oral and vulvovaginal candidiasis) were reported for seven patients, of whom three were treated with risankizumab and four with secukinumab [78].
Risankizumab 75 mg and 150 mg were well tolerated in a trial of 171 Japanese patients with moderate-to-severe psoriasis; rates of AEs and AEs were similar for patients treated with risankizumab and placebo, and no dose-dependent AEs were observed over 52 weeks of treatment [79]. One MACE (acute myocardial infarction; patient continued risankizumab treatment) and one malignancy (rectal carcinoma) were reported [79].
Long-term safety data for risankizumab 150 mg every 12 weeks are available from LIMMitless, an ongoing Phase 3, single-arm, open-label extension trial of patients who participated in Phase 2 and Phase 3 studies [80]. After up to 208 weeks of continuous risankizumab treatment (n = 897), the most commonly reported AEs (events per 100 PYs) were nasopharyngitis (17.3), URTI (10.7), arthralgia (3.8), headache (3.1), hypertension (2.8), back pain (2.8) and influenza (2.5) [80]. Rates of SAEs (6.7 events per 100 PYs) and AEs leading to discontinuation (1.4) were lower compared with the 16-week primary safety pool in the original clinical trials (n = 1306; 9.9 and 2.7 events per 100 PYs, respectively); rates of AEs of interest were 0.2 for MACE, 1.2 for serious infection, 0.5 for NMSC, 0.3 for malignancies excluding NMSC, < 0.1 for serious hypersensitivity reactions, and 0.6 for Candida infection [80].
Risankizumab remained well tolerated in real-world studies, most of which were small and retrospective; AEs were generally mild in severity, with no safety issues and few discontinuations due to AEs (Table 7). In the largest real-world study (N = 154) of risankizumab conducted in the Czech Republic in a population of 80% overweight/obese patients with psoriasis, four (3%) patients discontinued treatment due to an AE [81]. Similarly, in another larger study in 131 patients conducted in Italy, AEs were reported in five (4%) patients, and no severe AEs or AEs leading to discontinuation were reported [82].
Discussion
Many conditions must be considered when selecting the optimal therapy for patients with psoriasis [86, 87]. To date, cumulative data from both clinical trials and real-world practice settings suggest that anti–IL-23 p19 antibodies are very safe when treating patients with moderate-to-severe plaque psoriasis. Of particular importance, given the chronic nature of psoriasis, long-term use of IL-23 p19 inhibitors did not increase the risk of AEs of interest, including serious infection, MACE, and cancer, with up to 5 years of exposure.
Guselkumab had a favorable safety profile versus placebo and active controls in patients with psoriasis, according to results from the VOYAGE 1, VOYAGE 2, NAVIGATE, and ECLIPSE clinical trials. Long-term safety results (5 years) for guselkumab were consistent with those from short-term studies [28,29,30,31]; nonserious infection was the most commonly reported AE during long-term follow-up [30]. Tildrakizumab had a favorable safety profile in the reSURFACE 1 and reSURFACE 2 trials, with similar reported rates of severe infection, malignancies, and MACE among patients treated with tildrakizumab, placebo, and etanercept [60]. Data from tildrakizumab extension studies (5 years) were consistent with the results of the base studies; overall, severe infection, malignancy, and MACE rates did not increase during the extension period [61, 64]. Risankizumab was well tolerated in clinical trials, with similar rates of AEs between patients treated with risankizumab and placebo/comparator in multiple short-term trials [75,76,77,78]. Long-term data (up to 4 years) also support the safety of risankizumab [80].
Biologics targeting IL-23 p19 are also a safe long-term treatment option for patients with psoriasis who have a variety of clinical characteristics. Notably, data from real-world studies have extended the safety of guselkumab, tildrakizumab, and risankizumab in a broader population of patients with psoriasis, including older patients, patients for whom multiple previous biologics failed, and those with comorbidities, such as obesity, metabolic syndrome, cardiovascular disease, dyslipidemia, diabetes, hypertension, and PsA [38,39,40,41,42, 44, 69,70,71,72, 81, 82]. Based on the available data, safety concerns usually associated with inhibitors of IL-17 signaling [88] (oral candidiasis, induction or worsening of IBD, and suicidal ideation and behavior) occurred infrequently with IL-23 p19 inhibitors [30, 61, 77]. Similarly, these biologics have not been linked to increased risk of TB reactivation or to triggering or worsening of demyelinating disorders, as has been reported for anti-TNF biologics [30, 32, 61, 77, 88, 89].
During the COVID-19 pandemic, safety concerns were raised regarding the administration of immunosuppressive drugs and increased susceptibility to infection, as well as psoriasis exacerbation [90, 91]. Currently, there is no solid evidence linking IL-23 p19 inhibitors to the increased risk of SARS-CoV-2 infection or disease worsening for patients with psoriasis [90, 91].
Finally, despite the well-documented positive safety profile of this class of inhibitors, the life-long management of a chronic condition like psoriasis is still complex, especially in patients with comorbidities. In this scenario, the advent of personalized medicine could help in predicting and/or minimizing the risk of potential side effects [92]. However, to date, the data collected are insufficient to support clinicians in making treatment decisions; thus, more research in this direction is needed [92].
Strengths and Limitations
The strengths of this narrative review include the comprehensive summary of the available high-quality clinical trials and real-world evidence publications on IL-23 p19 inhibitors with a focus on their safety for patients with psoriasis. Several authors independently reviewed and selected the included studies to reduce possible information bias. Long-term follow-up studies are included. Emerging safety data on IL-23 p19 inhibitors for specific groups of patients with psoriasis, including older patients, patients for whom multiple biologics have failed, and patients with comorbidities, are also discussed.
This review is limited by the lack of direct comparisons among therapeutic agents due to differences among study designs and safety data reporting methods.
Conclusions
In summary, the favorable safety profiles of these agents, combined with ease of use for both patients and physicians, support the use of IL-23 p19 inhibitors in the long-term management of patients with moderate-to-severe plaque psoriasis.
References
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–6.
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–15.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.
Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94.
Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–22.
Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–912.
Boehncke WH, Brembilla NC. Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther. 2022;22(12):1463–73.
Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–34.
Janssen Biotech. STELARA (ustekinumab) [package insert]. Horsham: Janssen Biotech. 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed June 2023.
Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22(12):1503–20.
AbbVie. HUMIRA (adalimumab) [package insert]. 2021. North Chicago: AbbVie. https://www.rxabbvie.com/pdf/humira.pdf. Accessed June 2023.
UCB. CIMZIA (certolizumab pegol) [package insert]. 2019. Georgia: UCB. https://www.cimzia.com/themes/custom/cimzia/docs/CIMZIA_full_prescribing_information.pdf. Accessed June 2023.
Janssen Biotech. REMICADE (infliximab) [package insert]. 2021. Horsham: Janssen Biotech. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf. Accessed June 2023.
Amgen. ENBREL (etanercept) [package insert]. 2022. Thousand Oaks: Amgen. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Enbrel/enbrel_pi.pdf. Accessed June 2023.
Bausch Health. SILIQ (brodalumab) [package insert]. 2020. Bridgewater: Bristol-Myers Squibb. https://pi.bauschhealth.com/globalassets/BHC/PI/Siliq-pi.pdf. Accessed June 2023.
Eli Lilly. TALTZ (ixekizumab) [package insert]. 2022. Indianapolis: Eli Lilly. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf. Accessed June 2023.
Novartis. COSENTYX (secukinumab) [package insert]. 2021 East Hanover: Novartis. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf. Accessed June 2023.
De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFalpha therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673–82.
Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.
Janssen Biotech. TREMFYA (guselkumab) [package insert]. 2020. Horsham: Janssen Biotech. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed June 2023.
AbbVie. SKYRIZI (risankizumab-rzaa) [package insert]. 2022. North Chicago: AbbVie. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf. Accessed June 2023.
Sun Pharma Global. ILUMYA® (tildrakizumab-asmn) [package insert]. 2020. Sharjah: Sun Pharma Global. https://www.ilumya.com/pdfs/Sun_Pharma_ILUMYA_US_Prescribing_Information.pdf. Accessed June 2023.
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.
Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–23.
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–9.
Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180(5):1039–49.
Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–45.
Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827–34.
Blauvelt A, Lebwohl M, Langley RG, et al. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2023;S0190–9622(23):00524–8.
Puig L, Tsai TF, Bhutani T, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744–9.
Foley P, Reich K, Blauvelt A, et al. Serious gastrointestinal-related adverse events among psoriasis patients treated with guselkumab in VOYAGE 1 and VOYAGE 2. J Drugs Dermatol. 2021;20(8):855–60.
Reich K, Song M, Li S, et al. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019;46(12):1141–52.
Youn SW, Yu DY, Kim TY, et al. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: Post-hoc analysis from the phase III, double-blind, placebo- and active-comparator–controlled VOYAGE 1/2 trials. J Dermatolog Treat. 2022;33(1):535–41.
Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155(10):1153–61.
Blauvelt A, Thaçi D, Papp KA, et al. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. Br J Dermatol. 2023. https://doi.org/10.1093/bjd/ljad081.
Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560–4.
Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1): e14673.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2): e14798.
Rodriguez-Fernandez-Freire L, Galán-Gutiérrez M, Armario-Hita JC, Pérez-Gil A, Ruiz-Villaverde R. Guselkumab: short-term effectiveness and safety in real clinical practice. Dermatol Ther. 2020;33(3): e13344.
Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6): e13964.
Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–7.
Galluzzo M, Talamonti M, Bernardini N, et al. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opin Biol Ther. 2022;22(12):1585–92.
Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568–77.
Gerdes S, Bräu B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854–62.
Marletta D, Murgia G, Cattaneo A, Carrera C, Marzano A. Single-centre real-life experience of guselkumab in patients with moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2022;21(8):864–6.
Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–20.
Michelucci A, Manzo Margiotta F, Panduri S, et al. A real-life experience as a proof of guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatol Ther. 2022;35(4): e15339.
Medina-Catalán D, Riera P, Pagès-Puigdemont N, et al. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. Int J Clin Pharm. 2022;44(3):725–30.
Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205–12.
Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2022;33(2):1074–8.
Malara G, Trifirò C, Bartolotta A, et al. Real-world effectiveness and safety of guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci. 2021;25(1):406–12.
Maliyar K, O’Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. 2020;24(6):588–95.
Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.
Galluzzo M, Chiricozzi A, Cinotti E, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opin Biol Ther. 2022;22(3):367–76.
Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88.
Gooderham M, Elewski BE, Pariser DM, et al. Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: letter to the editor. J Eur Acad Dermatol Venereol. 2019;33(10):e350–2.
Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615–22.
Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–17.
Thaçi D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323–34.
Thaçi D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325–41.
Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. J Eur Acad Dermatol Venereol. 2022;36(10):1774–83.
Thaçi D, Jullien D, Egeberg A, et al. Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. J Eur Acad Dermatol Venereol. 2021;35(11):e709–11.
Bissonnette R, Fernández-Peñas P, Puig L, Mendelsohn AM, Rozzo SJ, Menter A. Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. J Eur Acad Dermatol Venereol. 2020;34(1):e21–4.
Menter MA, Mehta NN, Lebwohl MG, et al. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials (ReSURFACE 1 and ReSURFACE 2). J Drugs Dermatol. 2020;19(8):703–8.
Augustin M, Thaçi D, Pinter A, Reich K, Lambert J, van de Kerkhof P. Long-term efficacy and safety of tildrakizumab: 5-year results from the reSURFACE 1 and 2 phase III trials in patients with moderate-to-severe plaque psoriasis. EMJ Dermatol. 2021;9:2–11.
Imafuku S, Nakagawa H, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 5-year extension of a phase 3 study (reSURFACE 1). J Dermatol. 2021;48(6):844–52.
Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2022;37(1):85–92.
Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2022;37(1):93–103.
Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615–9.
Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343–54.
Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488.
Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:1–4.
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.
Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–86.
Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–58.
Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–9.
Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–94.
Papp KA, Lebwohl MG, Puig L, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135–45.
Gkalpakiotis S, Cetkovska P, Arenberger P, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic. Dermatol Ther (Heidelb). 2021;11(4):1345–55.
Gargiulo L, Ibba L, Pavia G, et al. Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309–24.
Caldarola G, Zangrilli A, Bernardini N, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6):e15489.
Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524.
Borroni RG, Malagoli P, Gargiulo L, et al. Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol. 2021;101(11):adv00605.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–84.
Mastorino L, Dapavo P, Trunfio M, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in northern Italy. Acta Derm Venereol. 2022;102:adv00821.
Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2.
Kašnar AM, Jurić K, Franić A, Čeović R. Current knowledge on psoriasis during the Covid-19 pandemic. Acta Dermatovenerol Croat. 2022;30(2):99–105.
Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–3.
Acknowledgements
Funding
The Rapid Service fee and the Open Access fee were funded by Sun Pharma.
Medical Writing/Editorial Assistance
Medical writing support was provided by Elisabetta Lauretti, PhD, of AlphaBioCom, a Red Nucleus company, and funded by Sun Pharma.
Author Contributions
All authors contributed equally and significantly to the development of this manuscript. All authors read, edited, and approved the final version of this manuscript.
Disclosures
Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant Sciences, Dermira Inc., FLX Bio, Galderma, Genentech/Roche, GlaxoSmithKline, Janssen, LEO Pharma, Lilly, Meiji, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron, Revance, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB, Valeant, and Vidac; and as a paid speaker for AbbVie, Regeneron, and Sanofi Genzyme. Andrea Chiricozzi has been an advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Almirall, LEO Pharma, Lilly, Janssen, Novartis, and Sanofi Genzyme. Benjamin D. Ehst has served as a consultant and/or clinical study investigator for AbbVie, Aclaris, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Dermira Inc., Lilly, Evelo Biosciences, Janssen, LEO Pharma, Novartis, Ortho, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB; and as a paid speaker for Dermavant, Incyte, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Regeneron, and Sanofi Genzyme. Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development LLC, Lilly, Ortho Dermatologics, Regeneron, and UCB; and is a consultant for Aditum Bio, Almirall, AltruBio Inc. AnaptysBio, Arcutis, Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Blauvelt, A., Chiricozzi, A., Ehst, B.D. et al. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review. Adv Ther 40, 3410–3433 (2023). https://doi.org/10.1007/s12325-023-02568-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-023-02568-0